Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To evaluate the effects of probiotic intervention on gastrointestinal function in patients with constipation after 4 weeks of treatment, and to explore its potential effects on immune status and bone metabolism.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Probiotic group A | Experimental | Probiotic powder containing GUT99 (1000B) administered orally once daily for 8 weeks. |
|
| Placebo group | Placebo Comparator | Maltodextrin powder administered orally once daily for 8 weeks. |
|
| Probiotic group B | Experimental | Probiotic powder containing GUT99 (120B) administered orally once daily for 8 weeks. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| GUT99 1 | Dietary Supplement | Taken orally once daily for 8 weeks (120B). |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in stool consistency | Stool consistency will be evaluated using the Bristol Stool Form Scale (BSFS) to assess the improvement of constipation symptoms in patients receiving probiotic intervention. | 8 weeks |
Not provided
Not provided
Inclusion Criteria:
Aged 18-65 years.
Patients with constipation, defined as fewer than three bowel movements per week and/or Bristol Stool Form Scale (BSFS) types 1-2.
Able to comply with the study protocol and complete the study procedures.
Participants who have voluntarily signed the informed consent form.
Participants (including male participants) must have no plans for pregnancy from 14 days before screening until 6 months after the end of the study and must agree to use effective contraception during this period.
-
Exclusion Criteria:
Individuals who have recently taken products with similar functions to the investigational product that may affect the evaluation of study outcomes.
Participants who plan to change their dietary habits during the study period.
Patients with severe allergies or immunodeficiency.
Women who are pregnant, breastfeeding, or planning to become pregnant.
Patients with severe diseases of major organs such as the cardiovascular system, lungs, liver, or kidneys, or those with severe metabolic diseases (e.g., diabetes or thyroid disorders), malignant tumors, or severe immune system diseases.
Individuals who have used antibiotics within the past two weeks.
Individuals with severe psychological or psychiatric disorders.
Participants who fail to take the investigational product as required or fail to attend scheduled follow-up visits, resulting in an inability to determine treatment efficacy.
Any other participants considered unsuitable for participation in the study by the investigator.
-
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Ying Jin, Doctor | Contact | 13375163966 | sunny13211@sina.com |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo |
| Dietary Supplement |
Taken orally once daily for 8 weeks. |
|
| GUT99 2 | Dietary Supplement | Taken orally once daily for 8 weeks (1000B). |
|